论文部分内容阅读
目的观察儿童哮喘肺泡灌洗液IL-33变化及孟鲁司特钠对其作用。方法选择哮喘患儿对照组和治疗组各35例,对照组常规治疗,治疗组在此基础上口服孟鲁司特钠。比较2组治疗前后肺泡灌洗液IL-33变化。结果 2组治疗前和治疗后1周差异无统计学意义(P>0.05),治疗4周后对照组(15.19±2.07)pg/ml,治疗组(10.06±2.24)pg/ml,治疗组浓度显著降低(P<0.01);治疗组不同喘息程度比较,轻度(16.17±1.90)pg/ml,中度(19.29±2.02)pg/ml,重度(24.50±0.71)pg/ml,提示哮喘越重,IL-33水平越高(P<0.01)。结论肺泡灌洗液IL-33可评价哮喘程度及疗效,孟鲁司特能降低肺泡灌洗液IL-33水平。
Objective To observe the changes of IL-33 in asthmatic bronchoalveolar lavage fluid and the effect of montelukast sodium on it. Methods The control group and the treatment group were selected from 35 asthmatic children with asthma. The control group received routine treatment. The treatment group received montelukast sodium on the basis of this treatment. The changes of IL-33 in bronchoalveolar lavage fluid before and after treatment were compared between the two groups. Results Before treatment and 1 week after treatment, there was no significant difference between the two groups (P> 0.05). After 4 weeks of treatment, the levels in the control group (15.19 ± 2.07) pg / ml and the treatment group (10.06 ± 2.24) pg / (16.17 ± 1.90) pg / ml, moderate (19.29 ± 2.02) pg / ml, and severe (24.50 ± 0.71) pg / ml, respectively, which suggested that asthma was more severe (P <0.01) Heavy, IL-33 levels were higher (P <0.01). Conclusion The bronchoalveolar lavage fluid IL-33 can evaluate the degree and effect of asthma. Montelukast can reduce the level of IL-33 in bronchoalveolar lavage fluid.